MDRX - Veradigm Inc.
After hours:
| Previous close | 11.89 |
| Open | 12.00 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 1300 |
| Day's range | 12.00 - 12.31 |
| 52-week range | 11.57 - 19.77 |
| Volume | |
| Avg. volume | 1,076,452 |
| Market cap | 1.344B |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | 13.67 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 07 Oct 2008 |
| 1y target est | N/A |
- Simply Wall St.
Investors Will Want Veradigm's (NASDAQ:MDRX) Growth In ROCE To Persist
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
- Simply Wall St.
Veradigm Inc. (NASDAQ:MDRX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
It is hard to get excited after looking at Veradigm's (NASDAQ:MDRX) recent performance, when its stock has declined 32...
- Simply Wall St.
Despite shrinking by US$50m in the past week, Veradigm (NASDAQ:MDRX) shareholders are still up 139% over 3 years
Veradigm Inc. ( NASDAQ:MDRX ) shareholders might be concerned after seeing the share price drop 26% in the last...
- Simply Wall St.
What Does Veradigm Inc.'s (NASDAQ:MDRX) Share Price Indicate?
While Veradigm Inc. ( NASDAQ:MDRX ) might not be the most widely known stock at the moment, it led the NASDAQGS gainers...
- Zacks
Syneos Health (SYNH) Signs New Partnership With Cryoport
Syneos Health (SYNH) inks a partnership with Cryoport to deliver seamless integration and insights for key services for cell and gene trial operations to biopharmaceutical customers.
- Simply Wall St.
An Intrinsic Calculation For Veradigm Inc. (NASDAQ:MDRX) Suggests It's 49% Undervalued
In this article we are going to estimate the intrinsic value of Veradigm Inc. ( NASDAQ:MDRX ) by taking the expected...
- Zacks
3 Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
- Simply Wall St.
Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To Persist
There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...
- Zacks
Allscripts (MDRX) Q3 Earnings Surpass Estimates, Margins Up
Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.
- Zacks
AllScripts Healthcare (MDRX) Q3 Earnings Top Estimates
AllScripts (MDRX) delivered earnings and revenue surprises of 21.05% and 0.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Allscripts Healthcare Solutions, Inc.'s (NASDAQ:MDRX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
It is hard to get excited after looking at Allscripts Healthcare Solutions' (NASDAQ:MDRX) recent performance, when its...
- Zacks
Analysts Estimate AllScripts Healthcare (MDRX) to Report a Decline in Earnings: What to Look Out for
AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Even though Allscripts Healthcare Solutions (NASDAQ:MDRX) has lost US$130m market cap in last 7 days, shareholders are still up 38% over 3 years
It might be of some concern to shareholders to see the Allscripts Healthcare Solutions, Inc. ( NASDAQ:MDRX ) share...
- Zacks
MDRX vs. OMCL: Which Stock Is the Better Value Option?
MDRX vs. OMCL: Which Stock Is the Better Value Option?
- Zacks
NextGen's (NXGN) Enterprise Adopted by Oak Orchard Health
NextGen's (NXGN) EHR and PM solution is expected to aid Oak Orchard Health in improving its workflow.
- Zacks
Here's Why You Should Hold on to Allscripts (MDRX) Stock Now
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
- Simply Wall St.
Is It Too Late To Consider Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)?
While Allscripts Healthcare Solutions, Inc. ( NASDAQ:MDRX ) might not be the most widely known stock at the moment, it...
- Zacks
MDRX vs. OMCL: Which Stock Should Value Investors Buy Now?
MDRX vs. OMCL: Which Stock Is the Better Value Option?
- Zacks
Can AllScripts (MDRX) Climb 27% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 26.9% in AllScripts (MDRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Zacks
Allscripts (MDRX) Q2 Earnings & Revenues Surpass Estimates
Allscripts' (MDRX) robust Q2 results demonstrate strength in both segments.
- Simply Wall St.
Allscripts Healthcare Solutions (NASDAQ:MDRX) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- Zacks
AllScripts Healthcare (MDRX) Tops Q2 Earnings and Revenue Estimates
AllScripts (MDRX) delivered earnings and revenue surprises of 12.50% and 2.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Earnings Preview: AllScripts Healthcare (MDRX) Q2 Earnings Expected to Decline
AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
- Zacks
Olink Holding AB publ Sponsored ADR (OLK) Surges 7.3%: Is This an Indication of Further Gains?
Olink Holding AB publ Sponsored ADR (OLK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
